Login to Your Account

Regulatory NEWS
A number of politicians, including President Obama, have jumped on the personalized medicine bandwagon, which a skeptic might say is a sure sign the idea will soon find itself mired in turf wars and ideological scrums.
Basilea Pharmaceutica Ltd.'s licensing partner Astellas Pharma Inc. won the favor of the FDA's Anti-Infective Drugs Advisory Committee for the antifungal isavuconazole, achieving a slam-dunk vote of 8-0 to recommend approval in the invasive aspergillosis indication, though the panel's balloting proved less certain about the rarer invasive mucormycosis: 8-2 in favor, with one abstention.

To say the PTO is gun-shy of media coverage and controversy would be an understatement, if its Sensitive Application Warning System (SAWS) is any indication.

More Regulatory Headlines

Cast Your Vote

Has biotech’s bubble burst?: